Mechanism of PH-dependent N-acetylgalactosamine Binding by a Functional Mimic of the Hepatocyte Asialoglycoprotein Receptor
Overview
Authors
Affiliations
Efficient release of ligands from the Ca(2+)-dependent carbohydrate-recognition domain (CRD) of the hepatic asialoglycoprotein receptor at endosomal pH requires a small set of conserved amino acids that includes a critical histidine residue. When these residues are incorporated at corresponding positions in an homologous galactose-binding derivative of serum mannose-binding protein, the pH dependence of ligand binding becomes more like that of the receptor. The modified CRD displays 40-fold preferential binding to N-acetylgalactosamine compared with galactose, making it a good functional mimic of the asialoglycoprotein receptor. In the crystal structure of the modified CRD bound to N-acetylgalactosamine, the histidine (His(202)) contacts the 2-acetamido methyl group and also participates in a network of interactions involving Asp(212), Arg(216), and Tyr(218) that positions a water molecule in a hydrogen bond with the sugar amide group. These interactions appear to produce the preference for N-acetylgalactosamine over galactose and are also likely to influence the pK(a) of His(202). Protonation of His(202) would disrupt its interaction with an asparagine that serves as a ligand for Ca(2+) and sugar. The structure of the modified CRD without sugar displays several different conformations that may represent structures of intermediates in the release of Ca(2+) and sugar ligands caused by protonation of His(202).
Maier I, Kontaxis G, Zimmermann C, Steininger C Biochemistry. 2024; 63(10):1270-1277.
PMID: 38770609 PMC: 11112747. DOI: 10.1021/acs.biochem.4c00113.
Donahue T, Ou C, Yang Q, Flinko R, Zhang X, Zong G ACS Chem Biol. 2023; 18(7):1611-1623.
PMID: 37368876 PMC: 10530246. DOI: 10.1021/acschembio.3c00229.
Glycomimetics for the inhibition and modulation of lectins.
Leusmann S, Menova P, Shanin E, Titz A, Rademacher C Chem Soc Rev. 2023; 52(11):3663-3740.
PMID: 37232696 PMC: 10243309. DOI: 10.1039/d2cs00954d.
ASGR1 and Its Enigmatic Relative, CLEC10A.
Hoober J Int J Mol Sci. 2020; 21(14).
PMID: 32650396 PMC: 7404283. DOI: 10.3390/ijms21144818.
An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.
Eggink L, Roby K, Cote R, Hoober J J Immunother Cancer. 2018; 6(1):28.
PMID: 29665849 PMC: 5905120. DOI: 10.1186/s40425-018-0339-5.